Close Menu

NEW YORK — ProMis Neurosciences, a Canadian developer of antibody therapeutics for neurodegenerative diseases, said on Wednesday that it has partnered with researchers from the University of British Columbia (UBC) to develop a test to assess immunity to SARS-CoV-2.

According to ProMis, it will work with a team led by UBC's Hans Frykman to develop a high-throughput serological assay that can detect the presence of SARS-CoV-2 antibodies. Such a test, the company said, could help identify who has virus immunity and who remains at risk for infection.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.